Abstract: The present disclosure provides a method for treating and/or preventing edematous fibrosclerotic panniculopathy (EFP) in a subject in need thereof. The method includes administering to the subject and effective amount of a pharmaceutical composition. The pharmaceutical composition includes a plurality of amphiphilic nanoparticles having one or more active ingredients encapsulated therein. Each of the amphiphilic nanoparticles is formed by a non-ionic surfactant, a polymeric carrier, or a lipid carrier. The hydrophilic-lipophilic balance (HLB) value of the non-ionic surfactant is greater than 9. The pharmaceutical composition is administered via a parenteral route by an injection, a microneedle, or an implant, or via topical administration or transdermal administration.

Abstract: A preparation method of a rhodium octanoate dimer includes the following steps: (1) mixing RhCl3 with an alkali metal octanoate uniformly to get a first solution; (2) adding a reductant into the first solution obtained from step (1), and heating for reflux reaction to get a second solution; (3) adding the second solution obtained from step (2) into deionized water while hot, continuing to stir, and performing a suction filtration to get a crude product; and (4) performing a primary washing, a secondary washing, a filtration, and a drying on the crude product obtained from step (3) to get a rhodium octanoate dimer as a green solid.

Abstract: A method for preparing FDCA with furfural as a raw material includes (1) pretreatment of the furfural: subjecting the furfural and an alcohol compound to an acetalization reaction under catalysis of an acidic ion resin to obtain an acetal compound of the furfural with the alcohol compound; (2) under stirring, adding the acetal compound dropwise to a mixed liquid of an acylation reagent and an ionic liquid (IL) to allow a reaction for 1 h to 2 h, adding a catalyst to continue the reaction for 3 h to 5 h, and subjecting a resulting reaction system to a post-treatment to obtain 5-acylfurfural; and (3) mixing the 5-acylfurfural with hydrogen peroxide, adding a catalyst to allow an oxidation reaction, and after the oxidation reaction is completed, subjecting a product to washing and recrystallization to obtain a white crystal, which is the FDCA.

Abstract: A method for preparing FDCA with furfural as a raw material includes (1) pretreatment of the furfural: subjecting the furfural and an alcohol compound to an acetalization reaction under catalysis of an acidic ion resin to obtain an acetal compound of the furfural with the alcohol compound; (2) under stirring, adding the acetal compound dropwise to a mixed liquid of an acylation reagent and an ionic liquid (IL) to allow a reaction for 1 h to 2 h, adding a catalyst to continue the reaction for 3 h to 5 h, and subjecting a resulting reaction system to a post-treatment to obtain 5-acylfurfural; and (3) mixing the 5-acylfurfural with hydrogen peroxide, adding a catalyst to allow an oxidation reaction, and after the oxidation reaction is completed, subjecting a product to washing and recrystallization to obtain a white crystal, which is the FDCA.

Abstract: Methods for alleviating a condition caused by abnormal subcutaneous deposit of adipose tissue or fat in a subject in need thereof an effective amount of a composition comprising a first active agent, which comprises (i) a resveratrol compound, a curcumin compound, a quercetin compound, a puerarin compound, or a combination thereof, and (ii) a pharmaceutically acceptable carrier.

Abstract: The present disclosure provides a pharmaceutical composition for reducing localized fat, comprising a pharmaceutically acceptable aqueous solution, drug-containing micelles made of surfactants, and resveratrol encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high fat tissue bioavailability, few side effects, and sustained release.

Abstract: The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.

Abstract: The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.

Abstract: A bicycle saddle includes a stack of fiber fabrics, a braided fiber bundle including two bundle segments, and a cured member. The cured member includes a first cured portion and a second cured portion. The first cured portion is configured to embed the stack of fiber fabrics therein to form a shell having a front nose portion and a rear widened portion. The second cured portion is bonded to and integrally formed with the first cured portion, and is configured to embed the braided fiber bundle therein to form two rails which respectively have the bundle segments therein. A method for making the bicycle saddle is also disclosed.

Abstract: The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.

Abstract: A hub motor assembly includes a hub axle, a hub shell, a motor unit, a cycloidal speed reducer, and a one-way clutch unit. When an output shaft of the motor unit rotates in a first direction about an axial line, a cycloidal wheel of the cycloidal speed reducer is driven to produce an eccentric cycloidal motion relative to the axial line, to thereby drive rotation of the hub shell in the first direction. When the output shaft rotates in a second direction opposite to the first direction, the hub shell is prevented from rotating with the output shaft.

Abstract: A hub motor assembly includes a hub axle, a hub shell, a motor unit, a cycloidal speed reducer, and a one-way clutch unit. When an output shaft of the motor unit rotates in a first direction about an axial line, a cycloidal wheel of the cycloidal speed reducer is driven to produce an eccentric cycloidal motion relative to the axial line, to thereby drive rotation of the hub shell in the first direction. When the output shaft rotates in a second direction opposite to the first direction, the hub shell is prevented from rotating with the output shaft.

Abstract: A bicycle saddle includes a stack of fiber fabrics, a braided fiber bundle including two bundle segments, and a cured member. The cured member includes a first cured portion and a second cured portion. The first cured portion is configured to embed the stack of fiber fabrics therein to form a shell having a front nose portion and a rear widened portion. The second cured portion is bonded to and integrally formed with the first cured portion, and is configured to embed the braided fiber bundle therein to form two rails which respectively have the bundle segments therein. A method for making the bicycle saddle is also disclosed.

Abstract: A probe pin includes: a reference axis extending along a longitudinal direction of the probe pin; a head portion, which includes, in a sequential order along the reference axis, a sensing end, at least one positioning recess, and a first spring engaging portion; a bottom portion, including a connecting end; and a spring, disposed between the top and bottom portions, wherein the spring encircles and engages with the first spring engaging portion, and abuts the bottom portion.

Abstract: The present invention provides a subcutaneous injection formulation for reducing body weight. The subcutaneous injection formulation for reducing body weight comprises drug-containing micelles made of a polyoxyethylene castor oil derivative or polyoxyethylene castor oil derivatives, and a curcuminoid or curcuminoids encapsulated in the drug-containing micelles. The subcutaneous injection formulation for reducing body weight can reduce body weight and visceral fat on overweight or obese subjects, and has the advantages of low dosage, high stability, high fat tissue bioavailability, few side effects, and sustained release.

Abstract: Provided is a plant extract composition and a pharmaceutical composition thereof for reducing body weight and body fat, wherein the plant extract composition comprises a green tea extract and a turmeric extract respectively 30 wt % to 75 wt % and 20 wt % to 55 wt % of a total weight of the composition. In diet-induced obesity models, either obesity is induced first or simultaneously with administration, the plant extract composition and a pharmaceutical composition thereof can reduce body weight and body fat more significantly than a single plant extract or commercially available weight loss drugs.

Abstract: The present invention provides a subcutaneous injection formulation for reducing body weight. The subcutaneous injection formulation for reducing body weight comprises drug-containing micelles made of a polyoxyethylene castor oil derivative or polyoxyethylene castor oil derivatives, and a curcuminoid or curcuminoids encapsulated in the drug-containing micelles. The subcutaneous injection formulation for reducing body weight can reduce body weight and visceral fat on overweight or obese subjects, and has the advantages of low dosage, high stability, high fat tissue bioavailability, few side effects, and sustained release.

Abstract: The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.

Abstract: The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.